From The Editor

1. AbbVie And Amgen's Blueprint To Digitalize Biomanufacturing 10/10/2025

   At BioProcess International 2025, leaders from AbbVie and Amgen gave keynote presentations about how their companies are advancing product development through digital tools.

2. On The Ground At BPI: Kat Kozyrytska On Ethical AI And Collaboration 9/29/2025

   AI consultant Kat Kozyrytska advocates for ethical AI adoption and explains its potential to foster collaboration across the industry.

3. On The Ground At BPI: Takeda's Amy Shaw On Scaling Cell Therapy Manufacturing 9/26/2025

   Takeda head of process development, Amy Shaw, explains what factors to consider when scaling up or scaling out cell therapy manufacturing.

4. On The Ground At BPI: Industry Reflections With Carl Schoellhammer, Ph.D. 9/25/2025

   DeciBio partner Carl Schoellhammer, Ph.D., speaks on the record with Bioprocess Online's chief editor Tyler Menichiello at the 2025 BioProcess International conference in Boston.

5. The Death Of A Dogma: David Baltimore And Lessons For Modern Drug Discovery 9/11/2025

   Nobel laureate, David Baltimore passed away at 87 years old, on September 6, 2025. He was widely regarded as a scientific visionary who at just 37, co-discovered reverse transcriptase, an enzyme that flipped molecular biology on its head by showing that genetic information could flow from RNA back to DNA, not just the other way around. 

6. Single-Use Standardization Starts At Home 8/28/2025

   During a Bioprocess Online Live event, “Single-Use Harmonization Needs A Tune Up," panelists discuss a way forward for the industry to unlock the true flexibility and promise of single-use technology.

7. Biopharma Manufacturing Outsourcing Is Flexible, Not Fractured 8/21/2025

   An element of the 2025 BioPlan Associates annual report and survey took Chief Editor Louis Garguilo by surprise. The report intimates that biopharmaceutical manufacturing faces a fractured CDMO market. Despite solid data to back that assertion up, Garguilo presents a very different view, one based on what many readers have expressed.

8. Unlocking The Pharmacological Potential Of Antibodies 8/20/2025

   Abalone Bio's CEO and co-founder, Richard Yu, Ph.D., explains the company's Functional Antibody Selection Technology (FAST) platform and its approach to developing a pipeline of G protein-coupled receptor (GPCR) mAbs.

9. Tech Transfer 2025 – A High-Stakes Game Of Trust 8/4/2025

   Trust us. You'll want to read this editorial from Chief Editor Louis Garguilo, who was (gently) reminded he hadn't visited the subject of tech transfer in a while. He answers the questions both sponsors and CDMOs ask to gain the trust to make a tech transfer work for both sides.

10. How Lumen Is Putting The "Farm" In Biopharma 7/31/2025

    Lumen Bioscience's SVP of production and development, Craig Behnke, Ph.D., explains how the company is cutting costs and rethinking upstream manufacturing with its algae-based production platform.